383 related articles for article (PubMed ID: 31310589)
1. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.
Suresh K; Naidoo J; Zhong Q; Xiong Y; Mammen J; de Flores MV; Cappelli L; Balaji A; Palmer T; Forde PM; Anagnostou V; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Lin CT; Feller-Kopman D; Lerner AD; Lee H; Shafiq M; Yarmus L; Lipson EJ; Soloski M; Brahmer JR; Danoff SK; D'Alessio F
J Clin Invest; 2019 Jul; 129(10):4305-4315. PubMed ID: 31310589
[TBL] [Abstract][Full Text] [Related]
2. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
[TBL] [Abstract][Full Text] [Related]
3. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.
Suresh K; Psoter KJ; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; Hales RK; D'Alessio F; Danoff SK; Naidoo J
J Thorac Oncol; 2019 Mar; 14(3):494-502. PubMed ID: 30503891
[TBL] [Abstract][Full Text] [Related]
4. Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis.
Franken A; Van Mol P; Vanmassenhove S; Donders E; Schepers R; Van Brussel T; Dooms C; Yserbyt J; De Crem N; Testelmans D; De Wever W; Nackaerts K; Vansteenkiste J; Vos R; Humblet-Baron S; Lambrechts D; Wauters E
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171010
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study.
Lin X; Lu T; Li S; Xie X; Chen X; Jiang J; Qin Y; Xie Z; Liu M; Ouyang M; Zhong N; Song Y; Zhou C
Clin Transl Oncol; 2021 Feb; 23(2):389-396. PubMed ID: 32613413
[TBL] [Abstract][Full Text] [Related]
6. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications.
Kim ST; Sheshadri A; Shannon V; Kontoyiannis DP; Kantarjian H; Garcia-Manero G; Ravandi F; Im JS; Boddu P; Bashoura L; Balachandran DD; Evans SE; Faiz S; Ruiz Vazquez W; Divenko M; Mathur R; Tippen SP; Gumbs C; Neelapu SS; Naing A; Wang L; Diab A; Futreal A; Nurieva R; Daver N
Front Immunol; 2020; 11():590494. PubMed ID: 33552049
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis.
Fuhrman C; Parrot A; Wislez M; Prigent H; Boussaud V; Bernaudin JF; Mayaud C; Cadranel J
Am J Respir Crit Care Med; 2001 Oct; 164(7):1186-91. PubMed ID: 11673207
[TBL] [Abstract][Full Text] [Related]
8. Metabolic landscape dysregulation in bronchoalveolar lavage fluid of checkpoint inhibitor pneumonitis.
Yu W; He Y; Shang Y; Guo T; Wang K; Liang H; Xue J; Ma X; Mu X; Li R; Gao Z
Clin Immunol; 2023 Feb; 247():109230. PubMed ID: 36646189
[TBL] [Abstract][Full Text] [Related]
9. Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: A case-control study.
Si X; Zheng X; Tian X; Wang H; Xu Y; Zhao J; Chen M; Zhong W; Wang M; Zhang L; Zhang X
Thorac Cancer; 2023 Jul; 14(21):2038-2044. PubMed ID: 37259819
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
Wang YN; Lou DF; Li DY; Jiang W; Dong JY; Gao W; Chen HC
Oncol Lett; 2020 Jul; 20(1):611-622. PubMed ID: 32565986
[TBL] [Abstract][Full Text] [Related]
11. Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
Li M; Spakowicz D; Zhao S; Patel SH; Johns A; Grogan M; Miah A; Husain M; He K; Bertino EM; Shields PG; Wei L; Carbone DP; Otterson GA; Presley CJ; Owen DH
Cancer Immunol Immunother; 2020 Nov; 69(11):2403-2408. PubMed ID: 32728772
[TBL] [Abstract][Full Text] [Related]
12. Airway infection in stable lung transplant patients is associated with decreased intracellular T-helper type 1 pro-inflammatory cytokines in bronchoalveolar lavage T-cell subsets.
Hodge G; Hodge S; Reynolds PN; Holmes M
Transpl Infect Dis; 2008 Apr; 10(2):99-105. PubMed ID: 17511818
[TBL] [Abstract][Full Text] [Related]
13. Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma.
Strippoli S; Fucci L; Negri A; Putignano D; Cisternino ML; Napoli G; Filannino R; De Risi I; Sciacovelli AM; Guida M
J Transl Med; 2020 Dec; 18(1):473. PubMed ID: 33302981
[TBL] [Abstract][Full Text] [Related]
14. Multiple rechallenges with anti-PD-1 immunotherapy in patients with checkpoint inhibitor-related pneumonitis: A report of two cases.
Yan Z; Yao S; Yuan J; Liu Y; Yao Z
J Oncol Pharm Pract; 2022 Jul; 28(5):1234-1238. PubMed ID: 35037786
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
Nishiyama O; Shimizu S; Haratani K; Isomoto K; Tanizaki J; Hayashi H; Yamazaki R; Oomori T; Nishikawa Y; Sano A; Nakagawa K; Tohda Y
BMC Pulm Med; 2021 May; 21(1):155. PubMed ID: 33964920
[TBL] [Abstract][Full Text] [Related]
16. Cellular and T-lymphocyte subpopulation profiles in bronchoalveolar lavage fluid from patients with acquired immunodeficiency syndrome and pneumonitis.
Wallace JM; Barbers RG; Oishi JS; Prince H
Am Rev Respir Dis; 1984 Nov; 130(5):786-90. PubMed ID: 6093655
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.
Suresh K; Naidoo J; Lin CT; Danoff S
Chest; 2018 Dec; 154(6):1416-1423. PubMed ID: 30189190
[TBL] [Abstract][Full Text] [Related]
18. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
19. Increased intracellular pro- and anti-inflammatory cytokines in bronchoalveolar lavage T cells of stable lung transplant patients.
Hodge G; Hodge S; Reynolds PN; Holmes M
Transplantation; 2005 Oct; 80(8):1040-5. PubMed ID: 16278583
[TBL] [Abstract][Full Text] [Related]
20. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
